Payment overview · 2025
General Payments
$71.22
4 reported records · 3 companies
Healthcare provider profile · identity verified
Brian A Moogerfeld, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STATESBORO, GA · NPI 1235287004
Verified facts
What the public records show
CMS Open Payments records show Brian A Moogerfeld, M.D. received $71.22 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.50 | 42.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.67 | 30.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.05 | 26.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $71.22 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 692 | 190 |
| Losartan Potassium | Losartan Potassium | 605 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 156 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 434 | 130 |
| Ezetimibe | Ezetimibe | 372 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 84 |
| Potassium Chloride | Potassium Chloride | 366 | 106 |
| Famotidine | Famotidine | 358 | 113 |
| Furosemide | Furosemide | 335 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 321 | 130 |
| Lisinopril | Lisinopril | 241 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 66 |
| Metformin Hcl | Metformin Hcl | 225 | 56 |
| Omeprazole | Omeprazole | 220 | 71 |
| Carvedilol | Carvedilol | 215 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 44 |
| Sertraline Hcl | Sertraline Hcl | 173 | 43 |
| Meloxicam | Meloxicam | 168 | 61 |
| Gabapentin | Gabapentin | 165 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 58 |
| Allopurinol | Allopurinol | 146 | 38 |
| Eliquis | Apixaban | 136 | 24 |
| Montelukast Sodium | Montelukast Sodium | 136 | 40 |
| Jardiance | Empagliflozin | 131 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 127 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 27 |
| Finasteride | Finasteride | 121 | 29 |
| Farxiga | Dapagliflozin Propanediol | 118 | 30 |
| Metformin Hcl Er | Metformin Hcl | 110 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 31 |
| Januvia | Sitagliptin Phosphate | 102 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 27 |
| Ozempic | Semaglutide | 86 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 13 |
| Alprazolam | Alprazolam | 81 | 17 |
| Donepezil Hcl | Donepezil Hcl | 81 | 26 |
| Ranolazine Er | Ranolazine | 74 | 18 |
| Tramadol Hcl | Tramadol Hcl | 73 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 27 |
| Prednisone | Prednisone | 67 | 43 |
| Glimepiride | Glimepiride | 66 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 47 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 64 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Atenolol | Atenolol | 60 | 16 |
| Alendronate Sodium | Alendronate Sodium | 56 | 20 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 14 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 15 |
| Celecoxib | Celecoxib | 51 | 11 |
| Ketoconazole | Ketoconazole | 48 | 27 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 45 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Azithromycin | Azithromycin | 41 | 37 |
| Tradjenta | Linagliptin | 41 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Ramipril | Ramipril | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Torsemide | Torsemide | 34 | 12 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 17 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $71.22 · 4 records | Amgen Inc. | LEQVIO, OTEZLA, REPATHA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error